Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,413.83 -11.02 -0.07%
S&P 500 1,866.12 3.81 0.20%
NASDAQ 4,096.72 10.50 0.26%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Avita Medical to Present at SoCalBio Investor Conference &

Avita Medical to Present at SoCalBio Investor Conference & Exhibition

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwire) -- 11/05/12 -- Regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) today announced that it will be presenting at the upcoming SoCalBio Investor Conference & Exhibition. The event will take place on November 7, 2012 at the Omni Hotel in Los Angeles, California.

The Company will be presenting in the Wound Healing & Regenerative Medicine Group.

"We are pleased to be presenting at this quality bioscience industry conference," said Dr. William Dolphin, Avita Medical's CEO. "ReCell(R) Spray-On Skin(TM) is on the market in other countries and undergoing FDA clinical trials in the US. This conference is a great venue to generate awareness among the US investment community as we approach FDA submission."

This is a one-day conference organized annually by the Southern California Biomedical Council (SoCalBio) to showcase the strength and future of the bioscience industry in Los Angeles/Orange County and neighboring communities. For more information on the conference:

ABOUT AVITA MEDICAL LTD. Avita Medical ( develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell(R) Spray-On Skin(TM), is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is on market and generating early revenues. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

Contact: Avita Medical Ltd. Stella Sung, Ph.D. Business Development Officer Phone:+1 838-352-9400 Email:

Investor Relations: ProActive Capital Resources Group, LLC Jeff Ramson CEO 641 Lexington Avenue, 6th Floor New York, NY. 10022 Phone:+1 646-863-6893 Email:

Sponsored Links
Sponsored Links